ALK and ROS1 non-small-cell lung cancer: TWO molecular subgroups sensitive to targeted therapy

The Lancet Respiratory Medicine

Volumn 2, Issue 12, 2014, Pages 966-968

  Rosell, Rafael ^a,b,c   Karachaliou, Niki ^b   Wolf, Juergen ^d,e   Ou, Sai Hong Ignatius ^f,g  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b Germans Trias i Pujol Research Institute   (Spain)

^c Molecular Oncology Research (MORe) Foundation   (Spain)

^d Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f Department of Radiology   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ALK GENE; BRAIN METASTASIS; CANCER RESISTANCE; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; NOTE; PROGRESSION FREE SURVIVAL; ROS1 GENE; TUMOR RECURRENCE; TUMOR REGRESSION; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84919652687     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70259-0     Document Type: Note

References (14)

1. Acquaviva J, Wong R, Charest A The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009, 1795:37-52.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
3. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17.
4. Ignatius Ou S-H, Klempner S, Greenbowe J, et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J Thorac Oncol (in press).
5. Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-Generation ALK inhibitor alectinib. Clin Cancer Res 2014, published online Sept 16. 10.1158/1078-0432.CCR-14-1511.
6. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-1197.
7. Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014, 20:1027-1034.
8. Yamada T, Takeuchi S, Nakade J, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res 2012, 18:3592-3602.
9. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014, 4:662-673.
10. Ignatius Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014, 9:549-553.
11. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014, 15:1119-1128.
12. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
13. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014, published online Sept 27. 10.1056/NEJMoa1406766.
14. Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013, 368:2395-2401.